혈액투석 및 복막투석 시장 예측(-2031년) : 제품 및 서비스별, 용도별, 최종사용자별, 지역별

The global hemodialysis and peritoneal dialysis market was valued at USD 102.7 billion in 2026 and is expected to reach USD 141.5 billion by 2031, growing at a CAGR of 6.6% during the forecast period. Rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD), driven by increasing rates of diabetes, hypertension, and aging populations worldwide, is the primary force behind market expansion.

Growing adoption of home-based dialysis therapies, supported by cost-containment policies in healthcare systems and payer reimbursement frameworks such as the Centers for Medicare & Medicaid Services (CMS) in the US, is broadening the patient base for both home hemodialysis and peritoneal dialysis. Expanding dialysis infrastructure in emerging markets across Asia Pacific, Latin America, and the Middle East and Africa is further adding to global patient volumes. High treatment costs and poor reimbursement for home hemodialysis in several markets outside North America remain constraints on faster adoption of home-based modalities.

"The HD access products subsegment is expected to register the highest CAGR among HD consumables during the forecast period."

Among the HD consumables and supplies segments, HD access products are projected to grow at the highest CAGR during the forecast period. Vascular access is a prerequisite for every hemodialysis session, and the structural demand it creates is consistent across care settings. Clinical guidelines from the National Kidney Foundation's KDOQI protocols, which prioritize arteriovenous fistula creation as the preferred access method, are driving procedure volumes and associated product consumption. The increasing use of tunneled hemodialysis catheters as a bridge to permanent access, the expanding patient population requiring long-term access management, and growing demand for single-use access needles and securement products are all contributing to this segment's growth. Dialyzers, the second-fastest-growing subsegment, are also benefiting from rising clinical adoption of high-flux and medium-cut-off membrane technologies that improve middle-molecule clearance relative to standard membranes.

"Hospitals accounted for the largest share of the global hemodialysis and peritoneal dialysis market in 2025."

By end user, hospitals held the largest share of the global hemodialysis and peritoneal dialysis market in 2025. Hospital-based dialysis units manage the full clinical complexity of the ESRD and AKI patient population, including newly diagnosed patients, those with significant comorbidities, and critical care patients requiring continuous renal replacement therapy. The concentration of specialized nephrology staff, dialysis equipment, and emergency infrastructure within hospital settings makes them the default point of care for patients initiating treatment. Independent dialysis centers collectively represent the largest channel but are distributed across a fragmented operator landscape, while hospitals manage a disproportionate share of high-acuity and newly incident patients. Home care settings are growing at the fastest rate among end users, driven by cost pressures in the healthcare system and the expansion of home dialysis program infrastructure.

"North America accounted for the largest share of the global hemodialysis and peritoneal dialysis market in 2025, while Asia Pacific is expected to register the highest CAGR during the forecast period."

North America accounted for the largest share of the global hemodialysis and peritoneal dialysis market in 2025. The US is the primary driver within this region, supported by a large and structurally growing ESRD patient population of more than 808,000 individuals, according to the United States Renal Data System 2023 Annual Data Report. A mature reimbursement framework under the Medicare ESRD Prospective Payment System, which covers dialysis services at a finalized base rate of USD 281.71 per treatment for calendar year 2026, provides consistent revenue visibility for both product suppliers and service operators. The region is also home to a concentrated network of dialysis facilities, with approximately 7,600 CMS-recognized ESRD centers and major global industry participants. Asia Pacific is the fastest-growing regional market. China and India are the primary growth engines, with government-backed universal CKD coverage programs and subsidized dialysis access schemes accelerating patient enrollment at dialysis centers in both countries.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the hemodialysis and peritoneal dialysis market.

• By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%)
• By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%)
• By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Fresenius Medical Care (Germany), Vantive (US), B. Braun (Germany), Nipro Corporation (Japan), Nikkiso Co., Ltd. (Japan), DaVita Inc. (US), Asahi Kasei Medical Co., Ltd. (Japan), Toray Medical Co., Ltd. (Japan), JMS Co., Ltd. (Japan), Outset Medical (US), and Rockwell Medical (US) are some of the key players in the global hemodialysis and peritoneal dialysis market.

Study Coverage: This research report categorizes the global hemodialysis and peritoneal dialysis market by product and service (hemodialysis market and peritoneal dialysis market), HD product & service (HD machines, HD consumables & supplies, and HD services), HD machine type (center-use HD machines and home-use HD machines), HD consumables type (dialyzers, bloodlines sets & tubes, hemodialysis concentrates/dialysates, HD access products, and others), HD service type (in-center hemodialysis services and home hemodialysis (HHD) services), PD product & service (PD concentrates/dialysates, PD machines, PD catheters, PD transfer sets, other PD products, and PD services), HD modality (conventional long-term hemodialysis, short daily hemodialysis, and nocturnal hemodialysis), PD modality [continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD)], disease indication (end-stage renal disease (ESRD), acute kidney injury (AKI), and others), end user (hospitals, independent dialysis centers, home care settings, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The report provides detailed information on the key factors driving growth in the global hemodialysis and peritoneal dialysis markets.

Key Benefits of Buying this Report

• Analysis of Key Drivers, Restraints, Opportunities, and Challenges: Gain insights into the principal factors shaping the global hemodialysis and peritoneal dialysis market, including rising CKD and ESRD prevalence, expanding home dialysis adoption, favorable reimbursement policies, high treatment costs, poor home HD reimbursement in select markets, digital health integration opportunities, and patient compliance challenges.
• Market Development: Understand current and projected market sizes across all product, service, modality, disease indication, end-user, and regional segments from 2024 to 2031, with base year data for 2025 and a complete historical series from 2024.
• Market Diversification: Identify high-growth pockets including HD access products, home hemodialysis services, home care settings, and the Asia Pacific regional market, along with country-level breakdowns for 20+ markets.
• Competitive Assessment: Evaluate the competitive positioning of key players including Fresenius Medical Care, Vantive, B. Braun, Nipro Corporation, Nikkiso Co., Ltd., DaVita Inc., Asahi Kasei Medical Co., Ltd., Toray Medical Co., Ltd., JMS Co., Ltd., Outset Medical, and Rockwell Medical, with analysis of their product portfolios, strategies, and recent commercial developments.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION
• 1.4 INCLUSIONS AND EXCLUSIONS
  • 1.4.1 YEARS CONSIDERED
  • 1.4.2 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 LIMITATIONS
• 1.7 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET OVERVIEW
• 3.2 ASIA PACIFIC: HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY END USER AND COUNTRY (2025)
• 3.3 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET: COUNTRY/REGION

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising prevalence of chronic kidney disease and end-stage renal disease
    • 4.2.1.2 Increasing aging population susceptible to kidney disorders
    • 4.2.1.3 Growing prevalence of diabetes and hypertension
    • 4.2.1.4 Continuous technological advancements in dialysis machines and consumables
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High cost of dialysis treatment and infrastructure
    • 4.2.2.2 Frequent product recalls and quality compliance issues
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expansion of dialysis centers and renal care infrastructure
    • 4.2.3.2 Investments in healthcare infrastructure in emerging markets
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Shortage of nephrologists and trained dialysis professionals
    • 4.2.4.2 Risk of dialysis-related infections and complications
• 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.3.1 UNMET NEEDS IN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
  • 4.5.1 STRATEGIC MOVES IN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 MANUFACTURERS
  • 5.5.2 END USERS
  • 5.5.3 REGULATORY BODIES
• 5.6 PRICING ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA (HS CODE 9018)
  • 5.7.2 EXPORT DATA FOR (HS CODE 9018)
• 5.8 REIMBURSEMENT SCENARIO
• 5.9 KEY CONFERENCES AND EVENTS, 2026-2027
• 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.11 INVESTMENT AND FUNDING SCENARIO
• 5.12 CASE STUDY ANALYSIS
• 5.13 IMPACT OF 2025 US TARIFF - HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET
  • 5.13.1 INTRODUCTION
  • 5.13.2 KEY TARIFF RATES
  • 5.13.3 PRICE IMPACT ANALYSIS
  • 5.13.4 IMPACT ON COUNTRIES/REGIONS
  • 5.13.5 IMPACT ON END-USE SEGMENTS
    • 5.13.5.1 Hospitals
    • 5.13.5.2 Independent dialysis centers
    • 5.13.5.3 Home care settings
    • 5.13.5.4 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1.1 High-volume hemodiafiltration (HDF)
    • 6.1.1.2 Intelligent home dialysis platforms
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Remote patient management platforms
    • 6.1.2.2 Advanced dialyzer membrane technology
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Portable & wearable artificial kidney technologies
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
  • 6.2.1 NEAR TERM (2025-2027)
  • 6.2.2 MID-TERM (2028-2030)
  • 6.2.3 LONG TERM (2030+)
• 6.3 PATENT ANALYSIS
  • 6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS
• 6.4 FUTURE APPLICATIONS
  • 6.4.1 AI-ASSISTED TREATMENT PLANNING AND THERAPY OPTIMIZATION
  • 6.4.2 PERSONALIZED DIALYSIS THERAPY
  • 6.4.3 CONNECTED DIALYSIS WORKFLOWS AND DIGITAL INTEGRATION
• 6.5 IMPACT OF AI/GEN AI ON HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET
  • 6.5.1 INTRODUCTION
  • 6.5.2 MARKET POTENTIAL OF AI IN HEMODIALYSIS AND PERITONEAL DIALYSIS
  • 6.5.3 AI USE CASES
  • 6.5.4 KEY COMPANIES IMPLEMENTING AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGULATORY LANDSCAPE
  • 7.1.1 REGULATORY FRAMEWORK
    • 7.1.1.1 North America
    • 7.1.1.2 Europe
    • 7.1.1.3 Asia Pacific
    • 7.1.1.4 Latin America
    • 7.1.1.5 Middle East & Africa
  • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 REDUCING MEDICAL WASTE & USE OF LOWER-IMPACT MATERIALS AND PACKAGING
  • 7.2.2 WATER, ENERGY, & RESOURCE EFFICIENCY
  • 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 HEMODIALYSIS MARKET, BY PRODUCT & SERVICE

• 9.1 INTRODUCTION
• 9.2 HEMODIALYSIS SERVICES
  • 9.2.1 IN-CENTER HEMODIALYSIS SERVICES
    • 9.2.1.1 Growing geriatric population and increasing government healthcare expenditure to drive segment
  • 9.2.2 HOME HEMODIALYSIS SERVICES
    • 9.2.2.1 Poor reimbursement scenario and high treatment costs to limit market growth
• 9.3 HEMODIALYSIS PRODUCTS
  • 9.3.1 HEMODIALYSIS MACHINES
    • 9.3.1.1 Center-use hemodialysis machines
      • 9.3.1.1.1 Rising number of renal care centers to aid segment growth
      • 9.3.1.1.2 Volume analysis of center-use hemodialysis machines, 2024-2031 (ten thousand units)
    • 9.3.1.2 Home-use hemodialysis machines
      • 9.3.1.2.1 Lesser hospital stays and better clinical outcomes to propel segment growth
      • 9.3.1.2.2 Volume analysis of home-use hemodialysis machines, 2024-2031 (ten thousand units)
  • 9.3.2 HEMODIALYSIS CONSUMABLES & SUPPLIES
    • 9.3.2.1 Dialyzers
      • 9.3.2.1.1 Dialyzers market, by material
        • 9.3.2.1.1.1 Synthetic dialyzers
          • 9.3.2.1.1.1.1 High physical strength and increased chemical resistance to drive segment
          • 9.3.2.1.1.1.2 Volume analysis of synthetic dialyzers, 2024-2031 (Ten Thousand Units)
        • 9.3.2.1.1.2 Cellulose-based dialyzers
          • 9.3.2.1.1.2.1 Affordability and high biocompatibility to support segment growth
          • 9.3.2.1.1.2.2 volume analysis of cellulose-based dialyzers, 2024-2031 (ten thousand units)
      • 9.3.2.1.2 Dialyzers market, by flux
        • 9.3.2.1.2.1 High-flux dialyzers
          • 9.3.2.1.2.1.1 High-flux dialyzers to command larger market share during forecast period
          • 9.3.2.1.2.1.2 Volume analysis of high-flux dialyzers, 2024-2031 (Ten Thousand units)
        • 9.3.2.1.2.2 Low-flux dialyzers
          • 9.3.2.1.2.2.1 Ability to filter small toxin particles to propel segment growth
          • 9.3.2.1.2.2.2 Volume analysis of low-flux dialyzers, 2024-2031 (Ten Thousand Units)
    • 9.3.2.2 Bloodline sets and tubes
      • 9.3.2.2.1 High pricing and reduced rate of reuse to limit market expansion
      • 9.3.2.2.2 Volume analysis of bloodline sets and tubes, 2024-2031 (Ten Thousand Units)
    • 9.3.2.3 Concentrates/Dialysates
      • 9.3.2.3.1 Alkaline concentrates
        • 9.3.2.3.1.1 Growing consumption before dialysis to boost segment growth
        • 9.3.2.3.1.2 Volume analysis of alkaline concentrates, 2024-2031 (Ten Thousand Units)
      • 9.3.2.3.2 Acidic concentrates
        • 9.3.2.3.2.1 Increased number of side effects to limit segment growth
        • 9.3.2.3.2.2 Volume analysis of acidic concentrates, 2024-2031 (Ten Thousand Units)
    • 9.3.2.4 Access products
      • 9.3.2.4.1 AV fistula needles
        • 9.3.2.4.1.1 Better blood flow and lower infection risk to aid segment growth
      • 9.3.2.4.2 AV grafts
        • 9.3.2.4.2.1 Increased number of patients requiring long-term dialysis to support segment growth
      • 9.3.2.4.3 Central venous catheters
        • 9.3.2.4.3.1 Increased use in temporary vascular access for short-term dialysis to boost segment growth
    • 9.3.2.5 Other hemodialysis consumables & supplies
      • 9.3.2.5.1 Volume analysis of other hemodialysis consumables, 2024-2031 (Ten Thousand Units)
• 9.4 HEMODIALYSIS MARKET, BY MODALITY
  • 9.4.1 CONVENTIONAL HEMODIALYSIS
    • 9.4.1.1 Technological advancements and rising number of dialysis centers to drive segment
  • 9.4.2 SHORT DAILY HEMODIALYSIS
    • 9.4.2.1 Improved blood pressure control and better calcium-phosphorus balance to augment segment growth
  • 9.4.3 NOCTURNAL HEMODIALYSIS
    • 9.4.3.1 Lower procedure costs to aid segment growth
• 9.5 HEMODIALYSIS WATER TREATMENT SYSTEMS MARKET, BY TYPE
  • 9.5.1 CENTRAL WATER DISINFECTION SYSTEMS
    • 9.5.1.1 Cost-effectiveness and easy maintenance to drive market
      • 9.5.1.1.1 Volume analysis of central water disinfection systems, 2024-2031 (Ten Thousand Units)
  • 9.5.2 PORTABLE WATER DISINFECTION SYSTEMS
    • 9.5.2.1 User-friendly operations and improved microbiological purity to support segment growth
      • 9.5.2.1.1 Volume analysis of portable water disinfection systems, 2024-2031 (Ten Thousand Units)

10 PERITONEAL DIALYSIS MARKET, BY PRODUCT & SERVICE

• 10.1 INTRODUCTION
• 10.2 PERITONEAL DIALYSIS PRODUCTS
  • 10.2.1 PERITONEAL DIALYSIS CONCENTRATES/DIALYSATES
    • 10.2.1.1 High demand for concentrates to boost segment growth
      • 10.2.1.1.1 Volume analysis of peritoneal dialysis concentrates/ dialysates, 2024-2031 (Ten Thousand Units)
  • 10.2.2 PERITONEAL DIALYSIS MACHINES
    • 10.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption
      • 10.2.2.1.1 Volume analysis of peritoneal dialysis machines, 2024-2031 (Ten Thousand Units)
  • 10.2.3 PERITONEAL DIALYSIS CATHETERS
    • 10.2.3.1 Favorable reimbursement policies to support market growth
      • 10.2.3.1.1 Volume analysis of peritoneal dialysis catheters, 2024-2031 (Ten Thousand Units)
  • 10.2.4 PERITONEAL DIALYSIS TRANSFER SETS
    • 10.2.4.1 Increasing number of patients in emerging economies to aid market growth
      • 10.2.4.1.1 Volume analysis of peritoneal dialysis transfer sets, 2024-2031 (Ten Thousand Units)
  • 10.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS
    • 10.2.5.1 Volume analysis of other peritoneal dialysis products, 2024-2031 (Ten Thousand Units)
• 10.3 PERITONEAL DIALYSIS SERVICES
  • 10.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET
• 10.4 PERITONEAL DIALYSIS MARKET, BY MODALITY
  • 10.4.1 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS
    • 10.4.1.1 Superior clearance of high-molecular-weight substances to drive market
  • 10.4.2 AUTOMATED PERITONEAL DIALYSIS
    • 10.4.2.1 Risk of rapid decline in residual renal functions to limit adoption

11 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 END-STAGE RENAL DISEASE
  • 11.2.1 RISING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
• 11.3 ACUTE KIDNEY INJURY
  • 11.3.1 INCREASING NUMBER OF HOSPITALIZATIONS TO PROPEL MARKET GROWTH
• 11.4 OTHER INDICATIONS

12 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 HOSPITALS
  • 12.2.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET
• 12.3 INDEPENDENT DIALYSIS CENTERS
  • 12.3.1 INCREASED DEMAND FOR ADVANCED DIALYSIS AND END-STAGE RENAL DISEASE TREATMENTS TO PROPEL MARKET GROWTH
• 12.4 HOME CARE SETTINGS
  • 12.4.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH
• 12.5 OTHER END USERS

13 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 13.2.2 NORTH AMERICA: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024-2031
  • 13.2.3 US
    • 13.2.3.1 US to dominate North American market during study period
  • 13.2.4 CANADA
    • 13.2.4.1 Shortage of dialysis facilities and increased treatment cost to restrain market expansion
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 EUROPE: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024-2031
  • 13.3.3 GERMANY
    • 13.3.3.1 Rising number of end-stage renal disease patients to boost market growth
  • 13.3.4 UK
    • 13.3.4.1 Expanding home dialysis programs and strong NHS support to drive market
  • 13.3.5 FRANCE
    • 13.3.5.1 Strong reimbursement framework and growing home dialysis adoption to fuel market
  • 13.3.6 ITALY
    • 13.3.6.1 Universal healthcare coverage and rising CKD burden to support market growth
  • 13.3.7 SPAIN
    • 13.3.7.1 Increasing CKD prevalence and expanding renal care infrastructure to drive market
  • 13.3.8 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024-2031
  • 13.4.3 CHINA
    • 13.4.3.1 Expanding dialysis infrastructure and large CKD patient base to drive market
  • 13.4.4 JAPAN
    • 13.4.4.1 Advanced dialysis infrastructure and universal reimbursement to support market growth
  • 13.4.5 INDIA
    • 13.4.5.1 Government-led dialysis expansion and rising CKD burden to fuel market
  • 13.4.6 AUSTRALIA
    • 13.4.6.1 High adoption of home dialysis and strong healthcare system to support market growth
  • 13.4.7 SOUTH KOREA
    • 13.4.7.1 Growing CKD burden and expanding renal care services to drive market
  • 13.4.8 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 LATIN AMERICA: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024-2031
  • 13.5.3 BRAZIL
    • 13.5.3.1 Large dialysis patient base and expanding renal care infrastructure to drive market
  • 13.5.4 MEXICO
    • 13.5.4.1 Healthcare reforms and expanding access to dialysis to support market growth
  • 13.5.5 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 13.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024-2031
  • 13.6.3 GCC COUNTRIES
    • 13.6.3.1 Kingdom of Saudi Arabia (KSA)
      • 13.6.3.1.1 Saudi Vision 2030 and expanding dialysis infrastructure to drive market
    • 13.6.3.2 United Arab Emirates (UAE)
      • 13.6.3.2.1 Growing investments in renal care and rising CKD burden to support market growth
    • 13.6.3.3 Other GCC countries
  • 13.6.4 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023-JUNE 2026
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET
• 14.3 REVENUE ANALYSIS
• 14.4 MARKET SHARE ANALYSIS
  • 14.4.1 GLOBAL HEMODIALYSIS MARKET SHARE ANALYSIS, 2025
    • 14.4.1.1 US hemodialysis market share analysis, 2025
    • 14.4.1.2 Europe hemodialysis market share analysis, 2025
  • 14.4.2 GLOBAL PERITONEAL DIALYSIS MARKET SHARE ANALYSIS, 2025
    • 14.4.2.1 US peritoneal dialysis market share analysis, 2025
    • 14.4.2.2 Europe peritoneal dialysis market share analysis, 2025
• 14.5 BRAND/PRODUCT COMPARISON
• 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 14.6.1 STARS
  • 14.6.2 EMERGING LEADERS
  • 14.6.3 PERVASIVE PLAYERS
  • 14.6.4 PARTICIPANTS
  • 14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 14.6.5.1 Company footprint
    • 14.6.5.2 Region footprint
    • 14.6.5.3 Hemodialysis product & service footprint
    • 14.6.5.4 Hemodialysis modality footprint
    • 14.6.5.5 Hemodialysis water treatment system type footprint
    • 14.6.5.6 Peritoneal dialysis product & service footprint
    • 14.6.5.7 Peritoneal dialysis modality footprint
    • 14.6.5.8 Hemodialysis and peritoneal dialysis application footprint
    • 14.6.5.9 Hemodialysis and peritoneal dialysis end user footprint
• 14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 14.7.1 PROGRESSIVE COMPANIES
  • 14.7.2 RESPONSIVE COMPANIES
  • 14.7.3 DYNAMIC COMPANIES
  • 14.7.4 STARTING BLOCKS
  • 14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 14.7.5.1 Detailed list of key startups/SMEs
    • 14.7.5.2 Competitive benchmarking of key startups/SMEs
• 14.8 COMPANY VALUATION AND FINANCIAL METRICS
  • 14.8.1 COMPANY VALUATION
  • 14.8.2 FINANCIAL METRICS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS
  • 14.9.4 OTHER DEVELOPMENTS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 FRESENIUS MEDICAL CARE AG
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products/Solutions/Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches & approvals
      • 15.1.1.3.2 Deals
      • 15.1.1.3.3 Expansions
      • 15.1.1.3.4 Other developments
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 DAVITA INC.
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products/Solutions/Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 VANTIVE
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products/Solutions/Services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches & approvals
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
      • 15.1.3.3.4 Other developments
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses & competitive threats
  • 15.1.4 U.S. RENAL CARE, INC.
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products/Solutions/Services offered
    • 15.1.4.3 MnM view
      • 15.1.4.3.1 Key strengths
      • 15.1.4.3.2 Strategic choices
      • 15.1.4.3.3 Weaknesses & competitive threats
  • 15.1.5 B. BRAUN SE
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products/Solutions/Services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Expansions
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses & competitive threats
  • 15.1.6 NIPRO CORPORATION
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products/Solutions/Services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product launches & approvals
      • 15.1.6.3.2 Deals
      • 15.1.6.3.3 Expansions
  • 15.1.7 DIAVERUM AB
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products/Solutions/Services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Deals
      • 15.1.7.3.2 Expansions
  • 15.1.8 ASAHI KASEI MEDICAL CO., LTD.
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products/Solutions/Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
      • 15.1.8.3.2 Other developments
  • 15.1.9 TORAY INDUSTRIES, INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products/Solutions/Services offered
  • 15.1.10 NIKKISO CO., LTD.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products/Solutions/Services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product launches & approvals
      • 15.1.10.3.2 Deals
  • 15.1.11 MOZARC MEDICAL
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products/Solutions/Services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Deals
  • 15.1.12 BD
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products/Solutions/Services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Deals
      • 15.1.12.3.2 Expansions
  • 15.1.13 JMS CO., LTD.
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products/Solutions/Services offered
  • 15.1.14 MERIT MEDICAL SYSTEMS
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products/Solutions/Services offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Deals
  • 15.1.15 TERUMO CORPORATION
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products/Solutions/Services offered
• 15.2 OTHER PLAYERS
  • 15.2.1 ALLMED MEDICAL PRODUCTS CO., LTD.
  • 15.2.2 OUTSET MEDICAL, INC.
  • 15.2.3 ROCKWELL MEDICAL, INC.
  • 15.2.4 AMERIWATER LLC
  • 15.2.5 DIALIFE SA
  • 15.2.6 QUANTA DIALYSIS TECHNOLOGIES LTD
  • 15.2.7 ISOPURE CORP.
  • 15.2.8 POLY MEDICURE LIMITED
  • 15.2.9 ATLANTIC BIOMEDICAL
  • 15.2.10 AMECATH

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Primary sources
    • 16.1.2.2 Key data from primary sources
    • 16.1.2.3 Key industry insights
    • 16.1.2.4 Breakdown of primaries
• 16.2 MARKET SIZE ESTIMATION
  • 16.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
  • 16.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
  • 16.2.3 APPROACH 3: TOP-DOWN APPROACH
  • 16.2.4 APPROACH 4: BOTTOM-UP APPROACH
  • 16.2.5 APPROACH 4: PRIMARY INTERVIEWS
  • 16.2.6 APPROACH 5: DEMAND-SIDE APPROACH
  • 16.2.7 APPROACH 6: VOLUME DATA ANALYSIS
• 16.3 DATA TRIANGULATION AND MARKET BREAKDOWN
• 16.4 MARKET SHARE ASSESSMENT
• 16.5 RESEARCH ASSUMPTIONS
  • 16.5.1 STUDY ASSUMPTIONS
  • 16.5.2 GROWTH RATE ASSUMPTIONS
• 16.6 RISK ASSESSMENT
• 16.7 RESEARCH LIMITATIONS

17 APPENDIX

• 17.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.2 CUSTOMIZATION OPTIONS
  • 17.2.1 PRODUCT ANALYSIS
  • 17.2.2 COMPANY INFORMATION
  • 17.2.3 GEOGRAPHIC ANALYSIS
• 17.3 RELATED REPORTS
• 17.4 AUTHOR DETAILS